There is a need for safe, effective antibacterial and anti-inflammatory agents for use in oral care compositions. Magnolia extract is known to contain compounds having antibacterial and/or anti-inflammatory properties, and such compounds have been the focus of considerable interest for use in oral care compositions. The use of such compounds in oral care compositions is described, for example, in WO2001/085116, WO 2011/106492 and WO 2011/106493, the contents of which application are incorporated herein by reference. Methods of synthesizing magnolol are disclosed, e,g, in WO 2011/106003. Synthetic non-natural analogs of various components of magnolia extract are also known to have antibacterial activity, but the compounds are in some cases expensive to synthesize.
Isomagnolol (3,3′-diallyl-biphenyl-2,2′-diol) and tetrahydro-isomagnolol, (3,3′-dipropyl-biphenyl-2,2′-diol), are broad spectrum antibacterial and anti-inflammatory agents with potential applications in oral care and personal care products. Existing synthetic methods involve costly reagents and poor yields. There is a need for simple, high yield synthetic procedures to make such compounds.
The invention provides a simple, efficient, two or three-step synthesis for isomagnolol derivatives, comprising O-alkylating biphenyl-2,2′-diol with an allyl halide, heating at reflux to obtain 3,3′-diallyl-biphenyl-2,2′-diol, and optionally reducing the allyl moieties to obtain (3,3′-dipropyl-biphenyl-2,2′-diol).
In another embodiment, the invention provides a novel and useful intermediate, 2,2′-di(allyloxy)-biphenyl.
Further areas of applicability of the present invention will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating the preferred embodiment of the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.
The invention thus provides a method (Method 1) for making isomagnolol (3,3′-diallyl-biphenyl-2,2′-diol) or tetrahydro-isomagnolol, (3,3′-dipropyl-biphenyl-2,2′-diol), comprising heating 2,2′-di(allyloxy)-biphenyl until it is substantially converted to 3,3′-diallyl-biphenyl-2,2′-diol,
In another embodiment, the invention provides 2,2′-di(allyloxy)-biphenyl, together with methods of making it comprising reacting biphenyl-2,2′-diol with an allyl halide, e.g., 3-chloroprop-1-ene or 3-bromoprop-1-ene, e.g., in the presence of a base, e.g. potassium carbonate, in the presence of a polar aprotic solvent, e.g., acetone, e.g., at reflux.
As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. In addition, all references cited herein are hereby incorporated by referenced in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.
Unless otherwise specified, all percentages and amounts expressed herein and elsewhere in the specification should be understood to refer to percentages by weight. The amounts given are based on the active weight of the material.
The invention is further described in the following examples. The examples are merely illustrative and do not in any way limit the scope of the invention as described and claimed.
In the first step of the synthesis, 2,2′-di(allyloxy)-biphenyl is made as follows, using either allyl bromide or allyl chloride to react with biphenyl-2,2′-diol:
3,3′-diallyl-biphenyl-2,2′-diol is made as follows, simply by heating the material of the previous example:
3,3′-diallyl-biphenyl-2,2′-diol is hydrogenated in the presence of a metal catalyst to obtain the title compound:
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/IN2013/000049 | 1/23/2013 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2014/115156 | 7/31/2014 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
6500409 | Scherl et al. | Dec 2002 | B1 |
8519197 | Reddy et al. | Aug 2013 | B2 |
8956592 | Yang et al. | Feb 2015 | B2 |
9000231 | Naik et al. | Apr 2015 | B2 |
9045397 | Naik et al. | Jun 2015 | B2 |
20120294812 | Fei et al. | Nov 2012 | A1 |
Entry |
---|
Alexakis et al., 2004, “Biphenol-Based Phosphoramidite Ligands for the Enantioselective Copper-Catalyzed Conjugate Addition of Diethylzinc,” The Journal of Organic Chemistry 69(17):5660-5667. |
Chattopadhyay et al., 2006, “Sequential Double Claisen Rearrangement and Two-Directional Ring-Closing Metathesis as a Route to Various Benzofused Bisoxepin and Bisoxocin Derivatives,” Synlett 2006(14):2211-2214. |
International Search Report and Written Opinion in International Application No. PCT/IN2013/000049, mailed Sep. 23, 2013. |
Kong et al., 2004, “Cytotoxic neolignans: an SAR study,” Bioorganic & Medicinal Chemistry Letters 15:163-166. |
Reinhoudt et al., 1981, “Crown ethers with converging neutral binding sites,” Tetrahedron 37(9):1753-1762. |
Sorell et al., 1985, “3,3′-Disubstituted 2,2′-biphenols. Synthesis of nonplanar, tetradentate chelating ligands,” The J. of Organic Chemistry 50(26):5765-5769. |
Written Opinion in International Application No. PCT/IN2013/000049 mailed Dec. 22, 2014. |
Number | Date | Country | |
---|---|---|---|
20150361017 A1 | Dec 2015 | US |